LEVOTHYROXINE SODIUM

Peak

levothyroxine sodium anhydrous

NDAINTRAVENOUSPOWDER
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3

Mechanism of Action

synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of…

Indications (1)

Clinical Trials (3)

NCT04037748Phase 1Completed

Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form

Started Jun 2019
72 enrolled
Healthy
NCT03094416Phase 4Completed

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

Started Jul 2018
66 enrolled
Hypothyroidism;Postablative
NCT01916304Phase 2Completed

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Started Jul 2013
101 enrolled
Hypothyroidism

Loss of Exclusivity

LOE Date
Oct 3, 2032
80 months away
Patent Expiry
Oct 3, 2032

Patent Records (3)

Patent #ExpiryTypeUse Code
9168238
Aug 29, 2032
Product
9168239
Aug 29, 2032
Product
9006289
Oct 3, 2032
Product